Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Actavis’ Big Bet On Diversified Hybrid Model Reflects Industry Trends

Executive Summary

Actavis’ proposal to buy Forest Labs for $25 billion in stock and cash was driven by consolidating customers and fierce competition in traditional Western markets. Different pressures, namely the tough-to-manage patent cliff, as well as leadership succession issues and investor unrest, drove Forest into the arms of a suitor.


Related Content

Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs
Pfizer’s Allergan Play Could Deliver Tax-Inversion, But No OTCs
Pfizer Tests The Luck Of The Irish; Will The US Let Its Pharma Pot Of Gold Go?
Copaxone’s Tombstone? 2014 Could Be Year Generic Launches, Momenta Says
Linzess Continues On Strong Launch Trajectory, Says Ironwood/Forest
Forest’s Board Grows, As Icahn Gains Second Director’s Seat
Deals Of The Week: Keeping Score – Valeant Wants Actavis, Which Covets Warner Chilcott …
Many New Products For Forest, But Not Enough To Fill The Lexapro Gap
Watson Begins Anew As Actavis, Focuses On Organic Growth
Watson Acquires Arrow Group And Expands Its Global Footprint


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts